Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
about
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine GliomaEphs and Ephrins in malignant gliomasSpatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeuticsPhase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.Glial progenitors as targets for transformation in glioma.Molecular profiling of childhood cancer: Biomarkers and novel therapiesPharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Diffuse intrinsic pontine glioma: a reassessment.The genetic signatures of pediatric high-grade glioma: no longer a one-act play.Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.Molecular biology of pediatric brain tumors and impact on novel therapies.Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.Managing teenage/young adult (TYA) brain tumors: a UK perspective.Oral Targeted Therapies and Central Nervous System (CNS) Metastases.Investigational new drugs for brain cancer.Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma.Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibitionChildren with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment.Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma.Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.Targeting Oncogene-Induced Autophagy: A New Approach in Cancer Therapy?
P2860
Q26801528-036511A0-98D7-44AD-AFDF-B1A65A573DD2Q27015780-641A97F3-D90C-4C5A-8CE4-E92D72C64F2BQ27317083-AB877D91-4C6B-4E16-8B26-DB60FB9F88AFQ34359662-512C0F4F-B997-42AC-8C04-AAEAB4F85D1AQ34735661-4879E9C6-02A9-4FEF-BC62-8B70F58E4113Q36250783-E3C740AB-9D14-4BB7-8F93-F8E21936B6B3Q36600202-B3C033E4-4B6C-4849-8433-717528FC3F61Q36918220-50E601DF-B857-4164-91F0-5C738B8305E8Q38160946-B28AE80B-AD2E-485B-8271-439E52689ACBQ38208998-8E953CFB-6259-4877-A2B2-0693A2AC023AQ38248990-C10A4C52-253F-49B9-AAE7-BF2C99528017Q38273428-24DE311B-C0D2-4709-9F74-642875967D09Q38359284-68310CB0-DA50-4207-9D96-8520B59FA110Q38363549-177349F5-8F13-4033-A01A-8DC6658EBF40Q38539466-D626F0BD-2460-4663-9940-08E099EBC788Q38631975-D1B4E525-5AF7-4DE8-B351-E85C807146C3Q38832510-3C83FC04-97CF-41B6-9229-831EF28E832BQ38926034-71FFEFC1-DC37-4692-A193-0A5057E37123Q39752215-E769F464-27EB-4AF4-BD61-16EA41592DA6Q40283574-4E3F315B-9940-4CC4-B6A8-F4AAED91B3DEQ41470815-A9DA77DA-DD84-4682-8168-A37AE51C03F3Q47140927-2FCFEF53-18AE-48AA-BC7B-14D755557795Q47955352-3FFC90CC-7DAA-4900-AE85-EABB97A3D8FCQ49244147-984F7AE4-9FBF-4EF5-BA3C-A991F4EF9C99Q50091855-92601543-37B6-42D1-B0B2-265EB51A9DB4Q51744172-271C4A00-8D2C-42BF-9718-1A207AD05048Q55351090-7035D002-2CD9-4FA8-BCEF-60C50C735A10Q55456561-041B4B48-8971-4C4B-9274-6A50FDF40E7FQ58919591-73851088-6A38-4906-95F1-C24AEE19B0D4
P2860
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.
@en
type
label
Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.
@en
prefLabel
Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.
@en
P2093
P2860
P1476
Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.
@en
P2093
Amar Gajjar
Andrew M Davidoff
Arzu Onar-Thomas
Atmaram S Pai Panandiker
Clinton F Stewart
Cynthia Wetmore
John C Panetta
Justin N Baker
Sue C Kaste
P2860
P304
P356
10.1158/1078-0432.CCR-13-0306
P407
P577
2013-03-27T00:00:00Z